In the main text our emphasis was on epidemiological data relevant to CML latencies, age-responses, and target cell numbers. A major goal was to show how epidemiological modeling extracts from radiobiological datasets information that can be used to design and calibrate clinically relevant CML models. A major goal in this supplement is to describe, as background information, clinically relevant models in their own right, including results that have minimal direct connection to radiobiological data. This is done in Section S1. Section S2 supplements the epidemiological data modeling of the main text with additional material; Section S3 provides links to R scripts that we developed for this review; and S4 gives the supplement bibliography.
S1. Clinically Relevant Mathematical CML Models

S1.1 Preliminary remarks
Cell population dynamics CML models emphasize such topics as molecular response to TKI treatment, immune response dynamics, the evolution and treatment of drug resistance, etc. We here review some of these topics, without aiming at completeness. Recent CML mathematical modeling papers whose bibliographies, taken together, cover the topics and papers omitted in this supplement are [Katouli & Komarova 2010; Tomasetti & Levy 2010; Wodarz 2010; Leder et al. 2011; Lenaerts et al. 2011; Paquin et al. 2011; Tang et al. 2011] . For reviews emphasizing mathematics and systems biology see [Roeder & d'Inverno 2009; Whichard et al. 2010] .
Distinctions can be made between exploratory, explanatory, and predictive biomathematical CML models.
Roughly speaking, exploratory models point out possible clinical implications of some mechanistically motivated calculations, often without systematic parameter calibration. Such models are frequently the first-step in formalizing non-mathematical conceptual models. They can be viewed as qualitative mathematical models.
Explanatory models uncover and interrelate biological mechanisms behind observed clinical data. Increased explanation plausibility involves: a) careful parameter calibration using mainly in vivo human data; b) consistency with all relevant, definitive human data; and c) applicability to many different aspects of CML. In general, explanatory models can be particularly useful as coherent summaries of diverse data sets obtained by many different groups, e.g. [Curto et al. 1998; Chen et al. 2000] .
The credibility of a predictive quantitative model depends on how well the model meets some more stringent criteria. Ideally the model should: a) give confidence intervals for all parameter estimates and numerical predictions; b) compare favorably to alternate models as regards goodness-of-fit relative to the number of freely estimated parameters it contains; and c) include some predictions that would have been difficult to develop without the aid of mathematical modeling and that were empirically substantiated after being predicted.
S1.2 Inside Pandora's box: CML LSC
The dynamics of CML LSC are the most important and least understood aspect of CML cell population dynamics. There is still much to be learned about LSC, and even about HSC [Shepherd et al. 2007; Carlesso & Cardoso 2010; Sloma et al. 2010; Catlin et al. 2011] . Better characterizations of CML LSC and their response to perturbations is the key to in-depth understanding of CML and its treatments. The most important clinical question is if, assuming no resistance mutations, the CML LSC subpopulation often becomes extinct during TKI treatment.
There is now considerable agreement that CML LSC must in principle be modeled stochastically, to take into account periods when there are only a few cells in a particular cell subpopulation -e.g. just after CML initiation, soon after a mutation that originates a drug resistant LSC subclone, after lengthy TKI treatment, or soon after a BMT. Deterministic calculations are regarded as approximations, typically applicable when the relevant subpopulation is large.
It is in their detailed view of LSC dynamics ( Figure S1 ) that different mathematical CML models differ most strongly. Most models use some version of Fig. S1 in modeling LSC, but they use, omit, emphasize, or alter different elements of Fig. S1 in different ways. For example many papers (e.g. [Tang et al. 2011] ) omit immune cell dynamics in the computations, whereas others (e.g. [Moore & Li 2004] ) emphasize immune system dynamics and condense or omit other elements of Fig. S1 . Similarly some models assume that quiescent CML LSC are relatively numerous, and that they are largely protected from damage because of their quiescence and their location in special bone marrow niches; other models do not distinguish between quiescent and cycling LSC (see subsection S.1.3). Additional differences concern the balance between symmetric and asymmetric division of CML LSC as well as the degree to which CML LSC compete with each other and with normal HSC. Roeder and coworkers have plausibly argued [Roeder & d'Inverno 2009 ] that assuming distinct subpopulations (rectangles in Fig. S1 ) tends to underestimate cell functional plasticity. CML cells are likely to exhibit different degrees of steminess in different microenvironments and may be able to revert from a state where they act as myeloid progenitors to a state where they act as LSC. The Roeder group favors mathematical models where the leukemic subpopulations shown in Fig. S1 are explicitly divided into many different sub-sub-populations and some de-differentiation is allowed (e.g. [Horn et al. 2008] ; mathematical aspects of this approach have meanwhile been simplified, e.g. [Kim et al. 2008b; Roeder et al. 2009] ).
Another CML model [Dingli et al. 2007a; Lenaerts et al. 2010 ] is distinctive in a number of ways: the number of stem cells is taken to be very small, with HSC+LSC = 400 cells, the LSC usually being in a small minority; stochasticity of LSC dynamics is strongly emphasized; and LSC in untreated patients, LSC under imatinib treatment, and HSC all have identical cell population dynamics, with differences occurring only in more differentiated cells. The main result is that, according to the model, diagnosis often occurs after all the CML LSC have differentiated and the only remaining stem cells are normal ones; for the parameters used this situation is estimated to occur 83% of time. Even after diagnosis, stochastic attrition of any remaining LSC continues. According to this picture, successful TKI therapy basically acts as a holding action, inhibiting progression and severe symptoms while the leukemia gradually cures itself as each CML cell subpopulation, from the LSC on downstream, gradually washes out, leaving only normal cells at that level of differentiation.
We wondered what this model would predict for various long term processes, such as continued blast crisis onset in untreated patients years after diagnosis [Sachs et al. 2011] , relapses after TKI discontinuation, development of resistance mutations, etc. We therefore designed an R script to implement the model as described in [Dingli et al. 2007a, b] , and checked that it reproduced the numerical results quoted in [Lenaerts et al. 2010] ; the script is available as open-source software (Table S.1, row 1). Computations using the script and the parameters of the published papers, confirmed that a large majority of untreated patients have no remaining CML LSC if they survive a few years after diagnosis. Using simple supplementary models we were not able to readily reconcile this prediction with observed patterns of blast crisis onset. It would be important to see if extending the model, possibly with parameter recalibration, could account for the observed patterns of CML progression.
S.1.3 Molecular response to TKI treatment
An influential 2005 paper [Michor et al. 2005] suggested the following:
• CML cells can be arranged in a hierarchy of four main subpopulations (Fig. S2 ), similar to a hierarchy for normal myeloid cells.
• The differences between normal, untreated leukemic, imatinib-treated leukemic cells, and imatinib resistant cells arising from mutations in CML LSC are primarily differences in cell multiplicative effects within the two middle compartments of Fig. S2 .
• During the time periods considered in the paper, LSC grow exponentially and are not affected by imatinib. Arrows show cell flux directions.
One implication of the model as regards first-line imatinib treatment was that, barring resistance mutations or CML progression, the molecular response to therapy (measured by RT-PCR for BCR-ABL mRNA) has two different phases corresponding to the time that it takes each of the two middle compartments to wash out. More specifically, the model asserts that the molecular response to imatinib dosing is an approximately bi-exponential BCR-ABL decay in time, where the two exponential decay constants of the response can be estimated using data on normal hematopoiesis. The paper emphasized the difficult and important task of parameter estimation.
Various recent calculations and data led to modifications and extensions of the 2005 model ( [Tang et al. 2011 ] and papers quoted therein). As in most other recent models, it was proposed that on longer time scales CML LSC growth is limited (i.e. sigmoid instead of purely exponential; data on this point are reviewed, e.g., in [Stein et al. 2011] ). Moreover, assuming, as is now also becoming the consensus view, that long-term TKI treatment has some inhibiting effect on cycling CML LSC, theoretical and observational evidence for a triexponential decay of BCR-ABL was given. Progress was made on parameter calibration to the point where error bars could be assigned to some of the parameters.
An encouraging feature is that the estimates of rates for HSC proliferation obtained in this joint analysis of normal and leukemic cells are roughly consistent with the estimates obtained, by stochastic modeling, in a recent paper [Catlin et al. 2011 ] that uses different data, including bone marrow transplant data and also new human in vivo data. We do not know of a model designed to analyze both TKI treatment and bone marrow transplants within a single mathematical framework.
However, overparametrization is perhaps still problematical in [Tang et al. 2011] . And there are still unresolved differences between the model and competing models; for example, if the hematopoietic differentiation hierarchy is as plastic and nearly continuous as suggested in [Roeder & d'Inverno 2009 ] then the bi-or tri-exponential decline would have to be replaced by a decline which in effect has a nearly continuously decreasing decay rate parameter.
S.1.4 Drug resistance mutations
Two papers [Komarova & Wodarz 2005; Michor et al. 2005] Mathematically, birth-death processes have been very thoroughly studied [Kimmel & Axelrod 2002; Tan 2002 ]. In the simplest case, one has constant birth and death parameters, B>0 and D≥0 respectively. Then B-D is essentially the Malthusian proliferation parameter whereas the ratio D/B, for given fixed B-D>0, is a key measure of how important stochastic effects are. For example, for D/B 1 stochastic effects become dominant and lead to predictions of: a) many divisions needed on average to achieve a given net growth; b) therefore, for
given per division mutation rates, many TKI resistance mutants at the time of diagnosis; and c), highly variable latency times. In this situation latency time variability and resistance mutation numbers are thus positively correlated.
Also seminal in the 2005 papers was the emphasis on point mutations within the ABL domain of leukemic cells, and on mutation rate per cell division as the key parameter. Some of the other assumptions made have been modified subsequently. Recent papers [Roeder & d'Inverno 2009; Katouli & Komarova 2010; Tomasetti & Levy 2010; Leder et al. 2011] review and extend the analyses. There is considerable agreement in these later papers, e.g. on the following points.
• Only mutations in CML LSC are important, not mutations in more differentiated cells.
• Resistance due to two or more successive mutations in one LSC subclone is so rare that it can be neglected, as can back mutations. However, some mutations confer resistance to more than one drug.
• A substantial fraction of the resistant mutants are already present, perhaps undetectably, at diagnosis.
• A cocktail of two different TKI should be considered for first-line treatment.
However, major uncertainties about CML LSC cell population dynamics remain, e.g. about the value of D/B.
There are also substantial quantitative uncertainties about point mutation rates. In addition, there are some less critical questions, e.g. about whether one should or should not neglect mutations that occur during asymmetric LSC division, where only one daughter remains in the LSC subpopulation. On balance, we suggest that these models of resistance mutations are exploratory and even explanatory but not yet predictive.
S.1.5 Progression to blast crisis
Untreated CML almost invariably progresses to a deadly blast crisis. Assuming that the malignant blasts originate by an additional alteration such as a mutation in a leukemic pre-blast cell, [Michor 2007 ] argued that in fact the blast predecessors must be leukemic progenitor cells rather than CML LSC, since TKI treatment rapidly reduces blast crises but not CML LSC. An alternate view [Wodarz 2008 ] is that blast crises arise not from an additional intra-cellular alteration but from snowballing distortions of feedback controls (see Fig. S1 ).
In [Sachs et al. 2011] we argued that the malignant blasts are so different from other CML cells that they probably do originate from an additional alteration heritable by daughter cells. We asked whether the alteration was a single-cell event like a mutation or, as is sometimes found for cancer progression, required intercellular interactions in an essential way. By extending a specific mathematical CML model [Foo et al. 2009 ] with stochastic mass action kinetics for blast crisis origination, we found that a mechanism based on interactions between normal hematopoietic cells and leukemic cells was compatible with a data set from the pre-imatinib era (when many more blast crises were observed). Within the framework of the model, mechanisms based on interactions among leukemic cells, or on autonomous single-cell alterations, were incompatible with the clinical data. A more detailed understanding of progression to blast crisis may supply useful clues on how other, less well understood, cancers progress.
S.1.6 Immune response to CML
Our discussion here of models analyzing CML interactions with the immune system will emphasize mathematical aspects without questioning the underlying immunological assumptions. A seminal model of such interactions [Moore & Li 2004] considers the number of naïve T cells (T n ), CML-specific effector T cells (T e ), and CML cells (C), as obeying Eqs. S1. 
Equations S1. Here symbols apart from the dynamic state variables (T n , T e and C) are constant parameters. Their meanings can be gleaned from the equations, e.g. 
Optimal load zone models
Subsequently a different model [Kim et al. 2008a ] of CML interactions with the immune system was developed. This model does not represent naïve and effector T cells separately, but does distinguish different CML differentiation stages, by extending the [Michor et al. 2005 ] model described in subsection S.1.3. The extension [Kim et al. 2008a ] differs from [Michor et al. 2005] in that it explicitly separates out CML cell death due to T-cell killing and adds an additional delay-differential equation to describe T cell dynamics. The impetus for this work was a recent finding that T-cells of patients in CML remission release TNF-α in response to autologous CML cells that were frozen down before the treatment began [Chen et al. 2008] .
The model state variables are population numbers T(t) for the T cells, and the column vector y(t)≡(y 0 (t), y 1 (t), y 2 (t), y 3 (t)) T (where T denotes the transpose) for 4 successively more differentiated CML subpopulations . (Fig S2) . A generalization that considers TKI resistant mutants in addition was also analyzed but is here omitted. The model equations can be written using the identity matrix I, a matrix M(t), and a function ζ(t) that incorporates non-linear coupling, as follows. The most important element of this model is a T cell activation factor This factor is part of the red term ( ) ( ).
that appears in the equation for dT/dt, as an immune system investment that is returned, as the blue term, with a 2 n -fold gain nτ days later (if the T cell survives its C cell encounter, which it does with probability q). We note that an activated T cell leaves the T subpopulation whether it lives or not, and that if it lives, it is gone while it undergoes its n divisions until it returns in greater numbers. A key point is the way depends on the leukemia cell number C, first increasing to a maximum as increases in C cause increases in the immune response, but then, when C increases further, decreasing exponentially, putatively due to either anergy or marrow crowding by CML. This behavior results in an optimal load zone wherein values of C(t) are high enough to activate T cells but not so high that they suppress the immune system. Kim et al. 
argue the following: (a) a practical implication of their model is that lethally irradiated CML cells (cancer vaccines) can add to C(t), thereby inducing an increase in T(t) large enough to eliminate the cancer; and (b), to be synergistic with imatinib the best vaccine injection time is when
T(t) is still rising toward its peak during the first 6-12 months of therapy. Here treatment brings C(t) down from its initial immunosuppressive level at diagnosis to a level that activates T cells against CML, and, if imatinib treatment continues without a vaccine, C(t) eventually becomes too low to be detected by T-cells. This model is
consistent with an immune system mediated impact on CML that becomes important only during or after firstline treatment.
( ) C t
The [Kim et al. 2008a ] model was subsequently used in an analysis of stopping imatinib treatment for 15 or 30 days [Paquin et al. 2011 ] that predicted that treatment-interruption-induced C(t) increases cause enough T cell stimulation/growth to kill off much more than the C(t) increase used to trigger the response, indeed, enough to achieve cures if the interruptions are strategically timed. The idea in this scenario is that patient specific imatinib interruption times can boost C(t) up enough to activate T(t) to kill C(t) subpopulations that imatinib itself cannot kill, such as LSC or CML progenitor cells with imatinib resistant mutations.
S.1.7 Model-assisted individualized therapy
Different treatments for different cancer types, particularly rare cancers, gender-dependent protocols, and decisions on how to treat the elderly to avoid high risks of treatment induced patient deaths, are current examples of steps toward more individualized therapies. Molecular characterization technology is advancing rapidly, and this will lead to further individualization, such as choosing different TKI or TKI cocktails for CML patients identified as having specific TKI resistant mutants among their CML LSC (see subsection S1.4).
Time scales for data used to inform differential patient treatments vary from a human lifetime (e.g. germline DNA sequences relevant to normal tissue toxicity), to the duration of the cancer type or its stage, to monitoring the state of the patient and cancer over intervals of hours to weeks ( Figure S3 ). Within this framework, to the extent that the CML models are individualized, so too will be the optimal dosing time courses they generate. If the cancer stage changes, new model "constants" can be identified, and thus new controls found, a procedure known as adaptive control [Astrom & Wittenmark 1994] . Individualized CML models could thus be used to assist, though not supplant, clinicians' judgment in designing individualized treatment protocols. This is what is meant here by model-assisted individualized therapy. It is through such venues that systems biology may have its greatest impact on medicine This section focuses on the mathematics of finding optimal individualized dosing time courses based on two different models of CML, one that represents interactions between CML cells and T-cells, [Moore & Li 2004; Nanda et al. 2007] and one that represents interactions between CML cells and their normal HSC or progenitor counterparts [Rubinow & Lebowitz 1976a, b; Ainseba & Benosman 2010] . Evidence for the former includes sustained CML remissions using interferon alpha alone, after stopping imatinib treatment [Burchert et al. 2010] . Rationales for the latter include the idea that the number of stem cell niches in the marrow is limited, so LSC must compete amongst themselves and with HSC to occupy niches, thereby in effect interacting (discussed for animal experiments and mathematically for humans in [Catlin et al. 2005] ). The rationale for induction therapy, namely that losses of malignant cells help normal cells rebound, also supports the idea that normal and leukemic cell populations compete.
Immune system interactions
The model in [Moore & Li 2004] , described in subsection S1.6, was used in two separate studies [Nanda et al. 2007; Padhi & Kothari 2007 ] to optimize drug timing. Eqs. S1 were modified as follows: 
Equations S3. Here u 1 (t) is a measure of the plasma concentration of imatinib, and u 2 (t) is a measure of the plasma concentration of a cytotoxic agent that kills not only CML cells but also T-cells. The dose time course system inputs u 1 (t) and u 2 (t) are optimized using calculus of variations.
One of the optimal control studies based on this model [Nanda et al. 2007 ] minimized the objective functional
J u t u t C t u t u t dt B C t B T t
over the time courses u 1 (t) and u 2 (t); the weights B 1 and B 2 define the importance of using minimal amounts of drugs relative to the importance of minimizing cancer burden over time, and B 3 and B 4 separately define the relative importance of the final outcome in terms of removing the cancer cells and sparing naïve T-cells (i.e.
limiting treatment toxicity), again relative to the integral of C(t). Optimization was done by applying Pontryagin's Principle [Bryson & Ho 1975 ] to a Hamiltonian based on the objective in Eq. S4 and the dynamic constraint of Eqs. S3. The net result of this approach is that, to find the optimal controls u 1 (t) and u 2 (t), the differential equations S3 must be coupled to an adjoint system of differential equations that has its state specified only at the final time point t F [Nanda et al. 2007] , so a two point "boundary" value problem must be solved (e.g. by using the R package bvpSolve), considering times t=0 and t=t F as the two boundary points. The B j in Eq. S4 are somewhat arbitrary. However, in our experience with industrial processes corresponding first guesses often performed acceptably well (i.e. control tends to be fairly robust to such choices).
Optimal controls based on Eqs. S3 were also developed by an independent group [Padhi & Kothari 2007] that used a more advanced approach wherein a neural network adaptively compensates for errors in the process model structure and its parameter estimates. An advantage of this approach is that it leads to a "closed-loop" control law [Kuo 1975 ] that depends on only current and previous state variable measurements, not an "openloop" control law that uses future predictions, as in the two point boundary value problem obtained from Eqs.
S3 and S4 where the current control effort depends on the current adjoint variables which depend on future state variables because the adjoint variables are integrated backwards in time from the final time point t F . A disadvantage is that neural networks are less mechanistic.
Interactions of CML with normal HSC and progenitor cells
Optimal control [Bryson & Ho 1975] has also been applied to another model [Ainseba & Benosman 2010] Meanings of the parameters can be inferred from the equations.
Ainseba & Benosman consider various sub-models of Eqs. S5 defined by different combinations of m s , δ m0s , and δ m1 either being constant or having a dependency on a measure u(t) of the imatinib concentration. The dependencies when present were that increases in u(t) lead to saturating increases ~ u/(1+u) in the death rate parameters δ m0s and δ m1 , and lead to birth rate multiplier m s decreases ~ 1/(1+u). The authors did not consider normal cell dependencies on u since such cells do not contain the bcr-abl drug target. For each sub-model Pontryagin's Principle [Bryson & Ho 1975] 
Summary
Applications of optimal control principles to CML models began only recently [Nanda et al. 2007; Padhi & Kothari 2007; Ainseba & Benosman 2010] . In general, the quality of a model-based controller depends heavily on the quality of the model on which it is based, and one might argue that current CML models are not highquality enough to warrant their use in control system design. To prove the value of model-based control in CML therapy, clinical trials could be designed where in one arm patients are modeled and optimal controls are thus suggested to the treating physician, and in the second arm patients are not modeled, and no suggestions are made. In such a trial individualized patient CML models could be updated every 6-12 months, or when disease changes are apparent, to lead to controllers that are adaptive across states of patient disease progression. It is likely that with this approach, CML therapies could eventually be individualized and optimized on both shortand long-term time scales ( Figure S3 ).
S1.8 Alternative approaches to CML treatment: manage or cure?
CML models can be useful in two basic approaches to therapy, corresponding to two different primary objectives [Hahnfeldt et al. 2003; Radivoyevitch et al. 2006] . In the return to normal (RN) approach, the goal is to return cancer cells to more normal cell states, e.g. use imatinib to bring bcr-abl kinase activity down to a level closer to that of normal cells; in the cell killing (CK) approach the goal is to kill CML LSC, e.g. as in graftversus-CML after an allogeneic BMT. The difference between these approaches is striking for bcr-abl targeted therapy: for the CK approach one seeks a drug that somehow channels high bcr-abl activity into a death signal, so in this approach greater therapeutic gains are expected with higher bcr-abl activity; in the RN approach, the goal is the opposite, i.e. minimizing bcr-abl activity differences between CML and normal hematopoietic cells, as achieved by imatinib. That the LSC-predecessor target cells of CML initiation must not have been addicted to bcr-abl before the bcr-abl translocation event occurred, or they would have been dead before the event happened (and CML would never occur), suggests that only differentiated progeny of the CML founder cell are strongly inhibited by imatinib, consistent with treatment for life unless the founder's LSC progeny happen to die out stochastically; in contrast, finding permanent cures (i.e. life without drugs) is the primary goal of CK by design. Thus the question of TKI action on LSC, already identified as key in the main text and in sections S1.2 and S1.3, is central to discussing the RN vs. CK approaches.
S1.9 Conclusions
In sum, two salient points seem to stand out.
• A better understanding of CML LSC is needed.
• Based on the model criteria in S.1.1, we would argue the following: at present there are no fully credible predictive CML mathematical models; such models are now within reach; but developing them will require systems methods, multidisciplinary interactions, and strong cooperation among different groups because of the large range of data types and of approaches that need to be integrated.
S2. Modeling Epidemiological Data
This section contains additional details about CML initiation and latency.
S2.1 CML initiation
CML initiation (Fig. 1B) produces an LSC carrying the BCR-ABL chromosome translocation. Dependence of chromosome translocations on age is discussed in the main text (e.g. Figs. 5 and 7) . Like CML, acute promyelocytic leukemia (APL) is also caused by translocations [Scaglioni & Pandolfi 2007] . Age dependence of adult onset background APL can be compared to that of CML (Fig. S4) . As regards CML-predecessor targets for initiation, it is not clear whether initiation simply involves a BCR-ABL translocation in an HSC, or if instead some other mechanism is involved, e.g. a BCR-ABL translocation in a myeloid progenitor cell as suggested in the discussion of Fig. 7 , or possibly intercellular interactions.
Somewhat surprisingly, many of the clinically relevant conclusions of standard mathematical CML models are almost completely independent of the specific initiation event. The reason is that almost all current clinical data concern diagnosed patients, in whom necessarily CML initiation followed by pronounced growth of CML LSC and progenitor cells has already occurred.
S2.2 CML latency
Radiobiological data relevant to the latency time T (Fig. 1B) has been discussed in detail in the main text (e.g.
Figs. 3 and 4). Probability densities shown in Fig. 3 for CML latency time T were obtained as follows. For the blue (radiobiology) curve we: a) used the estimates in [Preston et al. 1994 ] that the minimum waiting time is t = 2 yr. and the probability density is proportional to exp[-0.21*t] for t > 5 yr.; b) used a spline of the form a(t-2) 2 +b(t-2) 3 to interpolate smoothly across the interval 2<t<5; and c) normalized the result to an integral of one.
Doses > 4 Sv were excluded to avoid known confounding effects, e.g. extra cell killing, at high doses. The mean (8.3 yrs.) and SD (6.7 yrs.) are smaller than for other recent radiobiological estimates.
Before choosing the red curve in Fig.3 as reasonably representative for quantitative CML models that analyze clinical issues, we surveyed a number of models. The caption to Fig. S5 discusses many models which predict or assume that there is very little or no chance for any individual latency period greater than 10 years.
Likewise, in the supplement to [Leder et al. 2011] , 3 curves are given that are rather similar to the red curve in each has an SD of roughly 0.6 yr., there is some positive skewness, and all 3 go essentially to zero by ~10 yrs.
Finally, calculations using table C1 in [Kim et al. 2008b] , which applies to the stochastic model of [Horn et al. 2008] ), gave us a large mean ~12.5 yr. but a small SD ~0.65 yr. Monte-Carlo runs of our open-source R-script (Table S1 , row 1), developed using the assumptions and parameters in [Lenaerts et al. 2010] as described in subsection S.1.3, gave the curve shown. Of all the CML models examined, this one had the smallest mean and largest standard deviation SD.
As far as we were able to ascertain, no deterministic CML models allow latencies longer than 10 years (i.e. all have latency-time point estimates between 5 and 10 years and SD=0), also in contrast to the radiobiological evidence.
Thus, apart from the epidemiological model previously mentioned [Michor et al. 2006] , there seem to be no cell population dynamical CML models that allow for latency times as long as the 20 years suggested by some radiobiology analyses, let alone 50 years as suggested by some others.
S2.3 After diagnosis
Apart from radiobiological data, direct, in vivo, human data on latency are sparse. Latency is still not well understood. In contrast, the period following diagnosis (Fig. 1B) is the best understood and most clinically relevant period. However it is also the period least relevant to radiobiology, the least in need of radiobiological data, and one for which direct radiobiology data is in fact essentially nonexistent (unless the first-line treatment is a bone marrow transplant). Radiobiology data influences predictions about post-diagnosis events indirectly, by helping develop and parameterize an over-all model of all the different periods shown in Fig. 1B .
S3. R Scripts
R scripts used to generate plots can be found in the week3SEER and week4Abomb directories of http://epbiradivot.cwru.edu/EPBI473/files/, according to Table S1 . Table S1 . R scripts used for figures Figure S5 . Modeled CML latency period week3SEER/dingliCMLFINAL3.R Research Foundation. The SEER files must be processed into R binaries using mkPops.py, mkStx.py and mkSEERbinaryDFs.R in week3SEER. Figure 5 also requires tuck08.txt of this folder; this file holds the data in [Sigurdson et al. 2008] S4. Supplement References
